Understand why the Asia-Pacific region has become a key location for clinical trials

Understand why the Asia-Pacific region has become a key location for clinical trials


Asia’s vast population, being approximately 60% of the global population, and the focus on investments in infrastructure, specialised clinical trial centres and government support for clinical trials are key contributing factors to the region’s reputation as a hub for successful clinical trials. 

These factors, along with the advantages Australia and New Zealand bring, with Australia’s favourable R&D refund scheme and the pragmatic regulatory processes from respective countries, makes the Asia-Pacific a preferred destination for clinical trials. 

In a recently published whitepaper on “The Benefits of Asia-Pacific Clinical Trials for Biotechs”, Pharma Intelligence | Informa and Novotech surveyed respondents from biopharma companies across geographies to assess their clinical outsourcing needs and understanding of running trials in the Asia-Pacific (APAC) region. 
This whitepaper identifies the most commonly cited motivators for running clinical trials in the APAC region to be: 

  • Lower Costs 
  • Faster Patient recruitment 
  • Faster start-up 

Take advantage of the survey insights via downloading the whitepaper here: https://novotech-cro.com/whitepapers/benefits-asia-pacific-clinical-trials-biotechs

As Asia-Pacific’s biotech specialist CRO, get in touch with Novotech at BIO Digital this month to understand how you can leverage from and apply APAC’s regional advantages to your clinical development program. Don’t delay in connecting with Novotech via partnering to schedule a one-on-one meeting with our team or reach out to us at: https://novotech-cro.com/contact

The Asia-Pacific CRO